Covid-19 roundup: Pfiz­er, BioN­Tech set new pro­duc­tion quo­ta for vac­cine at 2B dos­es in 2021; New da­ta show IL-6 in­hibitor could be ef­fec­tive treat­ment af­ter all

Pfiz­er and BioN­Tech are well on their way to a glob­al roll­out of their mR­NA-based Covid-19 vac­cine, BTN162b2. Even with lo­gis­ti­cal chal­lenges ham­per­ing that plan, Ger­many’s BioN­Tech is plan­ning a vast ex­pan­sion of its pro­duc­tion ca­pac­i­ty in the com­ing year.

BioN­Tech plans to churn out more than 2 bil­lion dos­es of BNT162b2 in 2021, far out­pac­ing the 1 bil­lion dos­es tied up in sup­ply com­mit­ment around the globe, the com­pa­ny said in a vir­tu­al pre­sen­ta­tion at the vir­tu­al JP Mor­gan Health­care Con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER